John Neis
Directeur/Bestuurslid bij CELLECTAR BIOSCIENCES, INC.
Vermogen: 18 905 $ op 30-04-2024
Momenteel actieve connecties
Naam | Geslacht | Leeftijd | Verwante bedrijven | Samenwerking |
---|---|---|---|---|
Chad Kolean | M | 59 | 6 jaar | |
Thomas Mackie | M | 69 |
Novelos Therapeutics, Inc.
Novelos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Novelos Therapeutics, Inc. is a pharmaceutical company, which is engaged in the development of novel drugs for the treatment and diagnosis of cancer. It comprises of three cancer-targeted compounds: GLOW2, HOT and LIGHT, which are used for the treatment of cancer. Its therapeutic compounds directly kill cancer cells while minimizing harm to normal cells. This offers the potential for a paradigm shift in cancer therapy by providing efficacy in all three major drivers of mortality in cancer: primary tumors, metastases and stem cell-based relapse. Its LIGHT compound is a small-molecule cancer-targeted imaging agent, which is potential for selective detection of tumors and metastases in a broad range of cancers. Its HOT compound is a small-molecule, broad-spectrum, cancer-targeted molecular radio therapeutic that delivers radiation directly and selectively to cancer cells and cancer stem cells. Its GLOW2 compound is a small-molecule, broad-spectrum, cancer-targeted, non-radioactive optical imaging agent which is potential for intraoperative tumor margin illumination and non-invasive tumor imaging. The company was founded on June 21, 1996 and is headquartered in Madison, WI.
Cellectar, Inc.
Cellectar, Inc. Miscellaneous Commercial ServicesCommercial Services Cellectar, Inc. is a clinical stage radiopharmaceutical company that designs and develops products to detect, treat and monitor a wide variety of human cancers. Cellectar began independent lab activities in February 2003 after forming a company and raising initial funds in the 2000-2002 timeframe. Its product candidates combine phospholipids ethers analogs (PLEs), which are lipid-like molecules, with radioisotopes that destroy or image malignant cancer cells. Because only malignant tumor cells and tissues retain large amounts of these compounds, malignant cancer-selective retention of therapeutic or diagnostic doses of radioactivity can be achieved. Cellectar has demonstrated specific uptake and retention of its product candidates in more than 45 tumor types tested in proof-of-principle preclinical animal studies. In addition, ten preclinical experiments have shown anti-tumor activity in each tumor type studied including breast, prostate, lung, glioma, pancreatic, melanoma, ovarian, uterine, renal and colorectal cancers. The compound, originally known as NM404, is being taken through the regulatory process as CLR1404. Capitalizing on the unique characteristics of malignant cancer cells, Cellectar's molecules will be designed to find, treat and follow malignancies through the delivery of radiopharmaceuticals in a novel, highly selective way.
The Morgridge Institute for Research, Inc.
The Morgridge Institute for Research, Inc. Miscellaneous Commercial ServicesCommercial Services The Morgridge Institute for Research, Inc. is a biosciences research institution. The private company is based in Madison, WI. The CEO of the company is Brad Schwartz. | 9 jaar |
Aoy Tomita-Mitchell | M | - |
TAI Diagnostics, Inc.
TAI Diagnostics, Inc. BiotechnologyHealth Technology TAI Diagnostics, Inc. provides biotechnology services. It focuses on developing innovative diagnostic tests for monitoring the health of transplanted organs. The company was founded by Aoy Tomita-Mitchell and Michael E. Mitchell in 2015 and is headquartered in Wauwatosa, WI. | 9 jaar |
Fred Robertson | M | 68 |
TomoTherapy, Inc.
TomoTherapy, Inc. Medical SpecialtiesHealth Technology TomoTherapy, Inc. manufactures and provides radiation treatment systems for advanced radiation therapy. It provides radiation treatment services for cancer patients with its TomoTherapy Hi·Art System, which changes the intensity of the radiation beam so that it adapts to the shape of the tumor. The firm's system focuses on killing cancer cells while sparing healthy tissue. The company was founded by Thomas Rockwell Mackie and Paul J. Reckwerdt in 1997 and is headquartered in Madison, WI.
The Morgridge Institute for Research, Inc.
The Morgridge Institute for Research, Inc. Miscellaneous Commercial ServicesCommercial Services The Morgridge Institute for Research, Inc. is a biosciences research institution. The private company is based in Madison, WI. The CEO of the company is Brad Schwartz. | 7 jaar |
Scott White | M | 50 |
Delphinus Medical Technologies, Inc.
Delphinus Medical Technologies, Inc. Medical SpecialtiesHealth Technology Delphinus Medical Technologies, Inc. designs and develops ultrasound imaging devices and components. It offers the SoftVue, a tomographic ultrasound imaging device that scans women's breasts for the presence of masses. The firm supplies it solutions and services to hospitals and imaging clinics. The company also collaborates with imaging equipment manufacturers and distributors with focus on the breast cancer screening market. The company was founded by Neb Duric and Peter J. Littrup in 2009 and is headquartered in Novi, MI. | 1 jaar |
Michael E. Mitchell | M | - |
TAI Diagnostics, Inc.
TAI Diagnostics, Inc. BiotechnologyHealth Technology TAI Diagnostics, Inc. provides biotechnology services. It focuses on developing innovative diagnostic tests for monitoring the health of transplanted organs. The company was founded by Aoy Tomita-Mitchell and Michael E. Mitchell in 2015 and is headquartered in Wauwatosa, WI. | 9 jaar |
Mark J. Forchette | M | - |
Delphinus Medical Technologies, Inc.
Delphinus Medical Technologies, Inc. Medical SpecialtiesHealth Technology Delphinus Medical Technologies, Inc. designs and develops ultrasound imaging devices and components. It offers the SoftVue, a tomographic ultrasound imaging device that scans women's breasts for the presence of masses. The firm supplies it solutions and services to hospitals and imaging clinics. The company also collaborates with imaging equipment manufacturers and distributors with focus on the breast cancer screening market. The company was founded by Neb Duric and Peter J. Littrup in 2009 and is headquartered in Novi, MI. | - |
Brian Gillett | M | - |
Health Scholars, Inc.
Health Scholars, Inc. Information Technology ServicesTechnology Services Health Scholars, Inc. engages as a cloud-based, VR-ready training platform for the management, delivery, and analysis of clinical training. Its solutions include virtual reality training, and simulation management. The company was founded by Brian Gillett in 2017 and is headquartered in Westminster, CO. | 7 jaar |
James Caruso | M | 65 | 9 jaar | |
Neb Duric | M | - |
Delphinus Medical Technologies, Inc.
Delphinus Medical Technologies, Inc. Medical SpecialtiesHealth Technology Delphinus Medical Technologies, Inc. designs and develops ultrasound imaging devices and components. It offers the SoftVue, a tomographic ultrasound imaging device that scans women's breasts for the presence of masses. The firm supplies it solutions and services to hospitals and imaging clinics. The company also collaborates with imaging equipment manufacturers and distributors with focus on the breast cancer screening market. The company was founded by Neb Duric and Peter J. Littrup in 2009 and is headquartered in Novi, MI. | 15 jaar |
Jarrod Longcor | M | 51 | 8 jaar | |
Stefan Loren | M | 60 | 9 jaar | |
Asher Chanan-Khan | M | 55 | 3 jaar | |
Paul McCreadie | M | - |
Delphinus Medical Technologies, Inc.
Delphinus Medical Technologies, Inc. Medical SpecialtiesHealth Technology Delphinus Medical Technologies, Inc. designs and develops ultrasound imaging devices and components. It offers the SoftVue, a tomographic ultrasound imaging device that scans women's breasts for the presence of masses. The firm supplies it solutions and services to hospitals and imaging clinics. The company also collaborates with imaging equipment manufacturers and distributors with focus on the breast cancer screening market. The company was founded by Neb Duric and Peter J. Littrup in 2009 and is headquartered in Novi, MI. | - |
Joan Edelman Spero | M | 79 |
The Morgridge Institute for Research, Inc.
The Morgridge Institute for Research, Inc. Miscellaneous Commercial ServicesCommercial Services The Morgridge Institute for Research, Inc. is a biosciences research institution. The private company is based in Madison, WI. The CEO of the company is Brad Schwartz. | - |
Fred Driscoll | M | 74 | 7 jaar | |
Douglas Swirsky | M | 54 | 7 jaar | |
Andrew Held | M | - |
Virent, Inc.
Virent, Inc. Industrial SpecialtiesProcess Industries Virent, Inc. develops and commercializes biofuel technologies. It converts soluble biomass-derived sugars into products molecularly identical to those made with petroleum, including gasoline, diesel, jet fuel, and chemicals used for plastics and fibers. The company was founded by Randy D. Cortright and James Dumesic in 2002 and is headquartered in Madison, WI. | 17 jaar |
David Kettner | M | - |
Virent, Inc.
Virent, Inc. Industrial SpecialtiesProcess Industries Virent, Inc. develops and commercializes biofuel technologies. It converts soluble biomass-derived sugars into products molecularly identical to those made with petroleum, including gasoline, diesel, jet fuel, and chemicals used for plastics and fibers. The company was founded by Randy D. Cortright and James Dumesic in 2002 and is headquartered in Madison, WI. | 17 jaar |
Frank Langley | M | - |
TAI Diagnostics, Inc.
TAI Diagnostics, Inc. BiotechnologyHealth Technology TAI Diagnostics, Inc. provides biotechnology services. It focuses on developing innovative diagnostic tests for monitoring the health of transplanted organs. The company was founded by Aoy Tomita-Mitchell and Michael E. Mitchell in 2015 and is headquartered in Wauwatosa, WI. | - |
Peter Littrup | M | - |
Delphinus Medical Technologies, Inc.
Delphinus Medical Technologies, Inc. Medical SpecialtiesHealth Technology Delphinus Medical Technologies, Inc. designs and develops ultrasound imaging devices and components. It offers the SoftVue, a tomographic ultrasound imaging device that scans women's breasts for the presence of masses. The firm supplies it solutions and services to hospitals and imaging clinics. The company also collaborates with imaging equipment manufacturers and distributors with focus on the breast cancer screening market. The company was founded by Neb Duric and Peter J. Littrup in 2009 and is headquartered in Novi, MI. | 15 jaar |
Winslow Sargeant | M | - |
Venture Investors LLC
Venture Investors LLC Investment ManagersFinance Venture Investors LLC (Venture Investors) is a venture capital firm founded in 1984. The firm is headquartered in Madison, Wisconsin.
The Morgridge Institute for Research, Inc.
The Morgridge Institute for Research, Inc. Miscellaneous Commercial ServicesCommercial Services The Morgridge Institute for Research, Inc. is a biosciences research institution. The private company is based in Madison, WI. The CEO of the company is Brad Schwartz. | 11 jaar |
John Rowe | M | 78 |
The Morgridge Institute for Research, Inc.
The Morgridge Institute for Research, Inc. Miscellaneous Commercial ServicesCommercial Services The Morgridge Institute for Research, Inc. is a biosciences research institution. The private company is based in Madison, WI. The CEO of the company is Brad Schwartz. | - |
Deborah Keller | F | 61 |
The Morgridge Institute for Research, Inc.
The Morgridge Institute for Research, Inc. Miscellaneous Commercial ServicesCommercial Services The Morgridge Institute for Research, Inc. is a biosciences research institution. The private company is based in Madison, WI. The CEO of the company is Brad Schwartz. | - |
Shawn O’Brien | M | - |
Delphinus Medical Technologies, Inc.
Delphinus Medical Technologies, Inc. Medical SpecialtiesHealth Technology Delphinus Medical Technologies, Inc. designs and develops ultrasound imaging devices and components. It offers the SoftVue, a tomographic ultrasound imaging device that scans women's breasts for the presence of masses. The firm supplies it solutions and services to hospitals and imaging clinics. The company also collaborates with imaging equipment manufacturers and distributors with focus on the breast cancer screening market. The company was founded by Neb Duric and Peter J. Littrup in 2009 and is headquartered in Novi, MI. | - |
Debra Saunders | F | - |
Delphinus Medical Technologies, Inc.
Delphinus Medical Technologies, Inc. Medical SpecialtiesHealth Technology Delphinus Medical Technologies, Inc. designs and develops ultrasound imaging devices and components. It offers the SoftVue, a tomographic ultrasound imaging device that scans women's breasts for the presence of masses. The firm supplies it solutions and services to hospitals and imaging clinics. The company also collaborates with imaging equipment manufacturers and distributors with focus on the breast cancer screening market. The company was founded by Neb Duric and Peter J. Littrup in 2009 and is headquartered in Novi, MI. | - |
Edgar Steenwinkel | M | - |
Virent, Inc.
Virent, Inc. Industrial SpecialtiesProcess Industries Virent, Inc. develops and commercializes biofuel technologies. It converts soluble biomass-derived sugars into products molecularly identical to those made with petroleum, including gasoline, diesel, jet fuel, and chemicals used for plastics and fibers. The company was founded by Randy D. Cortright and James Dumesic in 2002 and is headquartered in Madison, WI. | 10 jaar |
Cole Sandau | M | - |
Health Scholars, Inc.
Health Scholars, Inc. Information Technology ServicesTechnology Services Health Scholars, Inc. engages as a cloud-based, VR-ready training platform for the management, delivery, and analysis of clinical training. Its solutions include virtual reality training, and simulation management. The company was founded by Brian Gillett in 2017 and is headquartered in Westminster, CO. | 6 jaar |
Brad Schwartz | M | - |
The Morgridge Institute for Research, Inc.
The Morgridge Institute for Research, Inc. Miscellaneous Commercial ServicesCommercial Services The Morgridge Institute for Research, Inc. is a biosciences research institution. The private company is based in Madison, WI. The CEO of the company is Brad Schwartz. | - |
Edward Lipsit | M | - |
Delphinus Medical Technologies, Inc.
Delphinus Medical Technologies, Inc. Medical SpecialtiesHealth Technology Delphinus Medical Technologies, Inc. designs and develops ultrasound imaging devices and components. It offers the SoftVue, a tomographic ultrasound imaging device that scans women's breasts for the presence of masses. The firm supplies it solutions and services to hospitals and imaging clinics. The company also collaborates with imaging equipment manufacturers and distributors with focus on the breast cancer screening market. The company was founded by Neb Duric and Peter J. Littrup in 2009 and is headquartered in Novi, MI. | - |
Marilyn Roubidoux | F | - |
Delphinus Medical Technologies, Inc.
Delphinus Medical Technologies, Inc. Medical SpecialtiesHealth Technology Delphinus Medical Technologies, Inc. designs and develops ultrasound imaging devices and components. It offers the SoftVue, a tomographic ultrasound imaging device that scans women's breasts for the presence of masses. The firm supplies it solutions and services to hospitals and imaging clinics. The company also collaborates with imaging equipment manufacturers and distributors with focus on the breast cancer screening market. The company was founded by Neb Duric and Peter J. Littrup in 2009 and is headquartered in Novi, MI. | - |
Bruno Dacquay | M | - |
Delphinus Medical Technologies, Inc.
Delphinus Medical Technologies, Inc. Medical SpecialtiesHealth Technology Delphinus Medical Technologies, Inc. designs and develops ultrasound imaging devices and components. It offers the SoftVue, a tomographic ultrasound imaging device that scans women's breasts for the presence of masses. The firm supplies it solutions and services to hospitals and imaging clinics. The company also collaborates with imaging equipment manufacturers and distributors with focus on the breast cancer screening market. The company was founded by Neb Duric and Peter J. Littrup in 2009 and is headquartered in Novi, MI. | - |
Bob Rozmiarek | M | - |
Virent, Inc.
Virent, Inc. Industrial SpecialtiesProcess Industries Virent, Inc. develops and commercializes biofuel technologies. It converts soluble biomass-derived sugars into products molecularly identical to those made with petroleum, including gasoline, diesel, jet fuel, and chemicals used for plastics and fibers. The company was founded by Randy D. Cortright and James Dumesic in 2002 and is headquartered in Madison, WI. | 19 jaar |
Thomas Krummel | M | 72 |
The Morgridge Institute for Research, Inc.
The Morgridge Institute for Research, Inc. Miscellaneous Commercial ServicesCommercial Services The Morgridge Institute for Research, Inc. is a biosciences research institution. The private company is based in Madison, WI. The CEO of the company is Brad Schwartz. | 9 jaar |
Alvin Vitangcol | M | 49 |
Health Scholars, Inc.
Health Scholars, Inc. Information Technology ServicesTechnology Services Health Scholars, Inc. engages as a cloud-based, VR-ready training platform for the management, delivery, and analysis of clinical training. Its solutions include virtual reality training, and simulation management. The company was founded by Brian Gillett in 2017 and is headquartered in Westminster, CO. | 5 jaar |
Thomas F. Pyle | M | 82 |
The Morgridge Institute for Research, Inc.
The Morgridge Institute for Research, Inc. Miscellaneous Commercial ServicesCommercial Services The Morgridge Institute for Research, Inc. is a biosciences research institution. The private company is based in Madison, WI. The CEO of the company is Brad Schwartz. | - |
Francis Dobscha | M | - |
Delphinus Medical Technologies, Inc.
Delphinus Medical Technologies, Inc. Medical SpecialtiesHealth Technology Delphinus Medical Technologies, Inc. designs and develops ultrasound imaging devices and components. It offers the SoftVue, a tomographic ultrasound imaging device that scans women's breasts for the presence of masses. The firm supplies it solutions and services to hospitals and imaging clinics. The company also collaborates with imaging equipment manufacturers and distributors with focus on the breast cancer screening market. The company was founded by Neb Duric and Peter J. Littrup in 2009 and is headquartered in Novi, MI. | 9 jaar |
Paul Weiss | M | 66 |
Venture Investors LLC
Venture Investors LLC Investment ManagersFinance Venture Investors LLC (Venture Investors) is a venture capital firm founded in 1984. The firm is headquartered in Madison, Wisconsin. | 18 jaar |
Joseph F. Amaral | M | 68 |
Venture Investors LLC
Venture Investors LLC Investment ManagersFinance Venture Investors LLC (Venture Investors) is a venture capital firm founded in 1984. The firm is headquartered in Madison, Wisconsin. | 5 jaar |
John Daniel Rice | M | 70 |
Virent, Inc.
Virent, Inc. Industrial SpecialtiesProcess Industries Virent, Inc. develops and commercializes biofuel technologies. It converts soluble biomass-derived sugars into products molecularly identical to those made with petroleum, including gasoline, diesel, jet fuel, and chemicals used for plastics and fibers. The company was founded by Randy D. Cortright and James Dumesic in 2002 and is headquartered in Madison, WI. | - |
Rachel Brem | M | 65 |
Delphinus Medical Technologies, Inc.
Delphinus Medical Technologies, Inc. Medical SpecialtiesHealth Technology Delphinus Medical Technologies, Inc. designs and develops ultrasound imaging devices and components. It offers the SoftVue, a tomographic ultrasound imaging device that scans women's breasts for the presence of masses. The firm supplies it solutions and services to hospitals and imaging clinics. The company also collaborates with imaging equipment manufacturers and distributors with focus on the breast cancer screening market. The company was founded by Neb Duric and Peter J. Littrup in 2009 and is headquartered in Novi, MI. | 5 jaar |
Hugo Braun | M | - |
Delphinus Medical Technologies, Inc.
Delphinus Medical Technologies, Inc. Medical SpecialtiesHealth Technology Delphinus Medical Technologies, Inc. designs and develops ultrasound imaging devices and components. It offers the SoftVue, a tomographic ultrasound imaging device that scans women's breasts for the presence of masses. The firm supplies it solutions and services to hospitals and imaging clinics. The company also collaborates with imaging equipment manufacturers and distributors with focus on the breast cancer screening market. The company was founded by Neb Duric and Peter J. Littrup in 2009 and is headquartered in Novi, MI. | 14 jaar |
John James McDonough | M | 87 |
TomoTherapy, Inc.
TomoTherapy, Inc. Medical SpecialtiesHealth Technology TomoTherapy, Inc. manufactures and provides radiation treatment systems for advanced radiation therapy. It provides radiation treatment services for cancer patients with its TomoTherapy Hi·Art System, which changes the intensity of the radiation beam so that it adapts to the shape of the tumor. The firm's system focuses on killing cancer cells while sparing healthy tissue. The company was founded by Thomas Rockwell Mackie and Paul J. Reckwerdt in 1997 and is headquartered in Madison, WI. | 20 jaar |
John Morgridge | M | 91 |
The Morgridge Institute for Research, Inc.
The Morgridge Institute for Research, Inc. Miscellaneous Commercial ServicesCommercial Services The Morgridge Institute for Research, Inc. is a biosciences research institution. The private company is based in Madison, WI. The CEO of the company is Brad Schwartz. | - |
Jim Adox | M | - |
Venture Investors LLC
Venture Investors LLC Investment ManagersFinance Venture Investors LLC (Venture Investors) is a venture capital firm founded in 1984. The firm is headquartered in Madison, Wisconsin. | 18 jaar |
Michael Gross | M | - |
Delphinus Medical Technologies, Inc.
Delphinus Medical Technologies, Inc. Medical SpecialtiesHealth Technology Delphinus Medical Technologies, Inc. designs and develops ultrasound imaging devices and components. It offers the SoftVue, a tomographic ultrasound imaging device that scans women's breasts for the presence of masses. The firm supplies it solutions and services to hospitals and imaging clinics. The company also collaborates with imaging equipment manufacturers and distributors with focus on the breast cancer screening market. The company was founded by Neb Duric and Peter J. Littrup in 2009 and is headquartered in Novi, MI. | 14 jaar |
A. Carlos Perez | M | 89 |
TomoTherapy, Inc.
TomoTherapy, Inc. Medical SpecialtiesHealth Technology TomoTherapy, Inc. manufactures and provides radiation treatment systems for advanced radiation therapy. It provides radiation treatment services for cancer patients with its TomoTherapy Hi·Art System, which changes the intensity of the radiation beam so that it adapts to the shape of the tumor. The firm's system focuses on killing cancer cells while sparing healthy tissue. The company was founded by Thomas Rockwell Mackie and Paul J. Reckwerdt in 1997 and is headquartered in Madison, WI. | 19 jaar |
David Arnstein | M | - |
Venture Investors LLC
Venture Investors LLC Investment ManagersFinance Venture Investors LLC (Venture Investors) is a venture capital firm founded in 1984. The firm is headquartered in Madison, Wisconsin. | - |
Arpesh Mehta | M | - |
Virent, Inc.
Virent, Inc. Industrial SpecialtiesProcess Industries Virent, Inc. develops and commercializes biofuel technologies. It converts soluble biomass-derived sugars into products molecularly identical to those made with petroleum, including gasoline, diesel, jet fuel, and chemicals used for plastics and fibers. The company was founded by Randy D. Cortright and James Dumesic in 2002 and is headquartered in Madison, WI. | - |
John Fowler | M | 73 |
TAI Diagnostics, Inc.
TAI Diagnostics, Inc. BiotechnologyHealth Technology TAI Diagnostics, Inc. provides biotechnology services. It focuses on developing innovative diagnostic tests for monitoring the health of transplanted organs. The company was founded by Aoy Tomita-Mitchell and Michael E. Mitchell in 2015 and is headquartered in Wauwatosa, WI. | - |
Cary J. Nolan | M | 81 |
TomoTherapy, Inc.
TomoTherapy, Inc. Medical SpecialtiesHealth Technology TomoTherapy, Inc. manufactures and provides radiation treatment systems for advanced radiation therapy. It provides radiation treatment services for cancer patients with its TomoTherapy Hi·Art System, which changes the intensity of the radiation beam so that it adapts to the shape of the tumor. The firm's system focuses on killing cancer cells while sparing healthy tissue. The company was founded by Thomas Rockwell Mackie and Paul J. Reckwerdt in 1997 and is headquartered in Madison, WI. | 23 jaar |
Frances S. Taylor | F | 77 |
TomoTherapy, Inc.
TomoTherapy, Inc. Medical SpecialtiesHealth Technology TomoTherapy, Inc. manufactures and provides radiation treatment systems for advanced radiation therapy. It provides radiation treatment services for cancer patients with its TomoTherapy Hi·Art System, which changes the intensity of the radiation beam so that it adapts to the shape of the tumor. The firm's system focuses on killing cancer cells while sparing healthy tissue. The company was founded by Thomas Rockwell Mackie and Paul J. Reckwerdt in 1997 and is headquartered in Madison, WI. | 18 jaar |
Ronald Ho | M | - |
Delphinus Medical Technologies, Inc.
Delphinus Medical Technologies, Inc. Medical SpecialtiesHealth Technology Delphinus Medical Technologies, Inc. designs and develops ultrasound imaging devices and components. It offers the SoftVue, a tomographic ultrasound imaging device that scans women's breasts for the presence of masses. The firm supplies it solutions and services to hospitals and imaging clinics. The company also collaborates with imaging equipment manufacturers and distributors with focus on the breast cancer screening market. The company was founded by Neb Duric and Peter J. Littrup in 2009 and is headquartered in Novi, MI. | - |
James A. Thomson | M | 65 |
The Morgridge Institute for Research, Inc.
The Morgridge Institute for Research, Inc. Miscellaneous Commercial ServicesCommercial Services The Morgridge Institute for Research, Inc. is a biosciences research institution. The private company is based in Madison, WI. The CEO of the company is Brad Schwartz. | 16 jaar |
Kristen High | F | 49 |
Health Scholars, Inc.
Health Scholars, Inc. Information Technology ServicesTechnology Services Health Scholars, Inc. engages as a cloud-based, VR-ready training platform for the management, delivery, and analysis of clinical training. Its solutions include virtual reality training, and simulation management. The company was founded by Brian Gillett in 2017 and is headquartered in Westminster, CO. | - |
Relatiegrafiek
Connectie in verschillende bedrijven
Oude connecties
Naam | Geslacht | Leeftijd | Verwante bedrijven | Samenwerking |
---|---|---|---|---|
Simon Pedder | M | 63 |
Novelos Therapeutics, Inc.
Novelos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Novelos Therapeutics, Inc. is a pharmaceutical company, which is engaged in the development of novel drugs for the treatment and diagnosis of cancer. It comprises of three cancer-targeted compounds: GLOW2, HOT and LIGHT, which are used for the treatment of cancer. Its therapeutic compounds directly kill cancer cells while minimizing harm to normal cells. This offers the potential for a paradigm shift in cancer therapy by providing efficacy in all three major drivers of mortality in cancer: primary tumors, metastases and stem cell-based relapse. Its LIGHT compound is a small-molecule cancer-targeted imaging agent, which is potential for selective detection of tumors and metastases in a broad range of cancers. Its HOT compound is a small-molecule, broad-spectrum, cancer-targeted molecular radio therapeutic that delivers radiation directly and selectively to cancer cells and cancer stem cells. Its GLOW2 compound is a small-molecule, broad-spectrum, cancer-targeted, non-radioactive optical imaging agent which is potential for intraoperative tumor margin illumination and non-invasive tumor imaging. The company was founded on June 21, 1996 and is headquartered in Madison, WI. | 2 jaar |
Stephen Hill | M | 65 |
Novelos Therapeutics, Inc.
Novelos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Novelos Therapeutics, Inc. is a pharmaceutical company, which is engaged in the development of novel drugs for the treatment and diagnosis of cancer. It comprises of three cancer-targeted compounds: GLOW2, HOT and LIGHT, which are used for the treatment of cancer. Its therapeutic compounds directly kill cancer cells while minimizing harm to normal cells. This offers the potential for a paradigm shift in cancer therapy by providing efficacy in all three major drivers of mortality in cancer: primary tumors, metastases and stem cell-based relapse. Its LIGHT compound is a small-molecule cancer-targeted imaging agent, which is potential for selective detection of tumors and metastases in a broad range of cancers. Its HOT compound is a small-molecule, broad-spectrum, cancer-targeted molecular radio therapeutic that delivers radiation directly and selectively to cancer cells and cancer stem cells. Its GLOW2 compound is a small-molecule, broad-spectrum, cancer-targeted, non-radioactive optical imaging agent which is potential for intraoperative tumor margin illumination and non-invasive tumor imaging. The company was founded on June 21, 1996 and is headquartered in Madison, WI. | 14 jaar |
John Patrick Genn | M | 67 |
Novelos Therapeutics, Inc.
Novelos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Novelos Therapeutics, Inc. is a pharmaceutical company, which is engaged in the development of novel drugs for the treatment and diagnosis of cancer. It comprises of three cancer-targeted compounds: GLOW2, HOT and LIGHT, which are used for the treatment of cancer. Its therapeutic compounds directly kill cancer cells while minimizing harm to normal cells. This offers the potential for a paradigm shift in cancer therapy by providing efficacy in all three major drivers of mortality in cancer: primary tumors, metastases and stem cell-based relapse. Its LIGHT compound is a small-molecule cancer-targeted imaging agent, which is potential for selective detection of tumors and metastases in a broad range of cancers. Its HOT compound is a small-molecule, broad-spectrum, cancer-targeted molecular radio therapeutic that delivers radiation directly and selectively to cancer cells and cancer stem cells. Its GLOW2 compound is a small-molecule, broad-spectrum, cancer-targeted, non-radioactive optical imaging agent which is potential for intraoperative tumor margin illumination and non-invasive tumor imaging. The company was founded on June 21, 1996 and is headquartered in Madison, WI.
Cellectar, Inc.
Cellectar, Inc. Miscellaneous Commercial ServicesCommercial Services Cellectar, Inc. is a clinical stage radiopharmaceutical company that designs and develops products to detect, treat and monitor a wide variety of human cancers. Cellectar began independent lab activities in February 2003 after forming a company and raising initial funds in the 2000-2002 timeframe. Its product candidates combine phospholipids ethers analogs (PLEs), which are lipid-like molecules, with radioisotopes that destroy or image malignant cancer cells. Because only malignant tumor cells and tissues retain large amounts of these compounds, malignant cancer-selective retention of therapeutic or diagnostic doses of radioactivity can be achieved. Cellectar has demonstrated specific uptake and retention of its product candidates in more than 45 tumor types tested in proof-of-principle preclinical animal studies. In addition, ten preclinical experiments have shown anti-tumor activity in each tumor type studied including breast, prostate, lung, glioma, pancreatic, melanoma, ovarian, uterine, renal and colorectal cancers. The compound, originally known as NM404, is being taken through the regulatory process as CLR1404. Capitalizing on the unique characteristics of malignant cancer cells, Cellectar's molecules will be designed to find, treat and follow malignancies through the delivery of radiopharmaceuticals in a novel, highly selective way. | 5 jaar |
Kathryn M. McNeil | F | 49 |
Novelos Therapeutics, Inc.
Novelos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Novelos Therapeutics, Inc. is a pharmaceutical company, which is engaged in the development of novel drugs for the treatment and diagnosis of cancer. It comprises of three cancer-targeted compounds: GLOW2, HOT and LIGHT, which are used for the treatment of cancer. Its therapeutic compounds directly kill cancer cells while minimizing harm to normal cells. This offers the potential for a paradigm shift in cancer therapy by providing efficacy in all three major drivers of mortality in cancer: primary tumors, metastases and stem cell-based relapse. Its LIGHT compound is a small-molecule cancer-targeted imaging agent, which is potential for selective detection of tumors and metastases in a broad range of cancers. Its HOT compound is a small-molecule, broad-spectrum, cancer-targeted molecular radio therapeutic that delivers radiation directly and selectively to cancer cells and cancer stem cells. Its GLOW2 compound is a small-molecule, broad-spectrum, cancer-targeted, non-radioactive optical imaging agent which is potential for intraoperative tumor margin illumination and non-invasive tumor imaging. The company was founded on June 21, 1996 and is headquartered in Madison, WI. | 2 jaar |
Paul Berns | M | 57 |
Novelos Therapeutics, Inc.
Novelos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Novelos Therapeutics, Inc. is a pharmaceutical company, which is engaged in the development of novel drugs for the treatment and diagnosis of cancer. It comprises of three cancer-targeted compounds: GLOW2, HOT and LIGHT, which are used for the treatment of cancer. Its therapeutic compounds directly kill cancer cells while minimizing harm to normal cells. This offers the potential for a paradigm shift in cancer therapy by providing efficacy in all three major drivers of mortality in cancer: primary tumors, metastases and stem cell-based relapse. Its LIGHT compound is a small-molecule cancer-targeted imaging agent, which is potential for selective detection of tumors and metastases in a broad range of cancers. Its HOT compound is a small-molecule, broad-spectrum, cancer-targeted molecular radio therapeutic that delivers radiation directly and selectively to cancer cells and cancer stem cells. Its GLOW2 compound is a small-molecule, broad-spectrum, cancer-targeted, non-radioactive optical imaging agent which is potential for intraoperative tumor margin illumination and non-invasive tumor imaging. The company was founded on June 21, 1996 and is headquartered in Madison, WI. | 3 jaar |
Harry Palmin | M | 54 |
Novelos Therapeutics, Inc.
Novelos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Novelos Therapeutics, Inc. is a pharmaceutical company, which is engaged in the development of novel drugs for the treatment and diagnosis of cancer. It comprises of three cancer-targeted compounds: GLOW2, HOT and LIGHT, which are used for the treatment of cancer. Its therapeutic compounds directly kill cancer cells while minimizing harm to normal cells. This offers the potential for a paradigm shift in cancer therapy by providing efficacy in all three major drivers of mortality in cancer: primary tumors, metastases and stem cell-based relapse. Its LIGHT compound is a small-molecule cancer-targeted imaging agent, which is potential for selective detection of tumors and metastases in a broad range of cancers. Its HOT compound is a small-molecule, broad-spectrum, cancer-targeted molecular radio therapeutic that delivers radiation directly and selectively to cancer cells and cancer stem cells. Its GLOW2 compound is a small-molecule, broad-spectrum, cancer-targeted, non-radioactive optical imaging agent which is potential for intraoperative tumor margin illumination and non-invasive tumor imaging. The company was founded on June 21, 1996 and is headquartered in Madison, WI. | 15 jaar |
Jamey P. Weichert | M | 67 |
Novelos Therapeutics, Inc.
Novelos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Novelos Therapeutics, Inc. is a pharmaceutical company, which is engaged in the development of novel drugs for the treatment and diagnosis of cancer. It comprises of three cancer-targeted compounds: GLOW2, HOT and LIGHT, which are used for the treatment of cancer. Its therapeutic compounds directly kill cancer cells while minimizing harm to normal cells. This offers the potential for a paradigm shift in cancer therapy by providing efficacy in all three major drivers of mortality in cancer: primary tumors, metastases and stem cell-based relapse. Its LIGHT compound is a small-molecule cancer-targeted imaging agent, which is potential for selective detection of tumors and metastases in a broad range of cancers. Its HOT compound is a small-molecule, broad-spectrum, cancer-targeted molecular radio therapeutic that delivers radiation directly and selectively to cancer cells and cancer stem cells. Its GLOW2 compound is a small-molecule, broad-spectrum, cancer-targeted, non-radioactive optical imaging agent which is potential for intraoperative tumor margin illumination and non-invasive tumor imaging. The company was founded on June 21, 1996 and is headquartered in Madison, WI. | 5 jaar |
Joanne M. Protano | F | 55 |
Novelos Therapeutics, Inc.
Novelos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Novelos Therapeutics, Inc. is a pharmaceutical company, which is engaged in the development of novel drugs for the treatment and diagnosis of cancer. It comprises of three cancer-targeted compounds: GLOW2, HOT and LIGHT, which are used for the treatment of cancer. Its therapeutic compounds directly kill cancer cells while minimizing harm to normal cells. This offers the potential for a paradigm shift in cancer therapy by providing efficacy in all three major drivers of mortality in cancer: primary tumors, metastases and stem cell-based relapse. Its LIGHT compound is a small-molecule cancer-targeted imaging agent, which is potential for selective detection of tumors and metastases in a broad range of cancers. Its HOT compound is a small-molecule, broad-spectrum, cancer-targeted molecular radio therapeutic that delivers radiation directly and selectively to cancer cells and cancer stem cells. Its GLOW2 compound is a small-molecule, broad-spectrum, cancer-targeted, non-radioactive optical imaging agent which is potential for intraoperative tumor margin illumination and non-invasive tumor imaging. The company was founded on June 21, 1996 and is headquartered in Madison, WI. | 8 jaar |
Azita Saleki-Gerhardt | M | 60 |
University of Wisconsin
| 8 jaar |
James Manuso | M | 75 |
Novelos Therapeutics, Inc.
Novelos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Novelos Therapeutics, Inc. is a pharmaceutical company, which is engaged in the development of novel drugs for the treatment and diagnosis of cancer. It comprises of three cancer-targeted compounds: GLOW2, HOT and LIGHT, which are used for the treatment of cancer. Its therapeutic compounds directly kill cancer cells while minimizing harm to normal cells. This offers the potential for a paradigm shift in cancer therapy by providing efficacy in all three major drivers of mortality in cancer: primary tumors, metastases and stem cell-based relapse. Its LIGHT compound is a small-molecule cancer-targeted imaging agent, which is potential for selective detection of tumors and metastases in a broad range of cancers. Its HOT compound is a small-molecule, broad-spectrum, cancer-targeted molecular radio therapeutic that delivers radiation directly and selectively to cancer cells and cancer stem cells. Its GLOW2 compound is a small-molecule, broad-spectrum, cancer-targeted, non-radioactive optical imaging agent which is potential for intraoperative tumor margin illumination and non-invasive tumor imaging. The company was founded on June 21, 1996 and is headquartered in Madison, WI. | 7 jaar |
David G. Angerbauer | M | 64 |
University of Utah
| 8 jaar |
Donald A. Johnson | M | - |
University of Wisconsin
| 11 jaar |
Dan Rauchle | M | 60 |
University of Wisconsin
| 7 jaar |
A. Michael Heimert | M | - |
University of Wisconsin
| 5 jaar |
Jeff Jacob | M | - |
University of Wisconsin
| 6 jaar |
Yu Neng Lim | M | 61 |
University of Wisconsin
| 5 jaar |
Howard M. Schneider | M | 80 |
Novelos Therapeutics, Inc.
Novelos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Novelos Therapeutics, Inc. is a pharmaceutical company, which is engaged in the development of novel drugs for the treatment and diagnosis of cancer. It comprises of three cancer-targeted compounds: GLOW2, HOT and LIGHT, which are used for the treatment of cancer. Its therapeutic compounds directly kill cancer cells while minimizing harm to normal cells. This offers the potential for a paradigm shift in cancer therapy by providing efficacy in all three major drivers of mortality in cancer: primary tumors, metastases and stem cell-based relapse. Its LIGHT compound is a small-molecule cancer-targeted imaging agent, which is potential for selective detection of tumors and metastases in a broad range of cancers. Its HOT compound is a small-molecule, broad-spectrum, cancer-targeted molecular radio therapeutic that delivers radiation directly and selectively to cancer cells and cancer stem cells. Its GLOW2 compound is a small-molecule, broad-spectrum, cancer-targeted, non-radioactive optical imaging agent which is potential for intraoperative tumor margin illumination and non-invasive tumor imaging. The company was founded on June 21, 1996 and is headquartered in Madison, WI. | 9 jaar |
Michael F. Tweedle | M | 73 |
Novelos Therapeutics, Inc.
Novelos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Novelos Therapeutics, Inc. is a pharmaceutical company, which is engaged in the development of novel drugs for the treatment and diagnosis of cancer. It comprises of three cancer-targeted compounds: GLOW2, HOT and LIGHT, which are used for the treatment of cancer. Its therapeutic compounds directly kill cancer cells while minimizing harm to normal cells. This offers the potential for a paradigm shift in cancer therapy by providing efficacy in all three major drivers of mortality in cancer: primary tumors, metastases and stem cell-based relapse. Its LIGHT compound is a small-molecule cancer-targeted imaging agent, which is potential for selective detection of tumors and metastases in a broad range of cancers. Its HOT compound is a small-molecule, broad-spectrum, cancer-targeted molecular radio therapeutic that delivers radiation directly and selectively to cancer cells and cancer stem cells. Its GLOW2 compound is a small-molecule, broad-spectrum, cancer-targeted, non-radioactive optical imaging agent which is potential for intraoperative tumor margin illumination and non-invasive tumor imaging. The company was founded on June 21, 1996 and is headquartered in Madison, WI. | 3 jaar |
Andrew L. Nelson | M | - |
University of Wisconsin
| 7 jaar |
Wai Keung Leung | M | 66 |
University of Wisconsin
| 3 jaar |
Dan Nickow | M | - |
University of Wisconsin
| 5 jaar |
Kevin Kozak | M | - |
Novelos Therapeutics, Inc.
Novelos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Novelos Therapeutics, Inc. is a pharmaceutical company, which is engaged in the development of novel drugs for the treatment and diagnosis of cancer. It comprises of three cancer-targeted compounds: GLOW2, HOT and LIGHT, which are used for the treatment of cancer. Its therapeutic compounds directly kill cancer cells while minimizing harm to normal cells. This offers the potential for a paradigm shift in cancer therapy by providing efficacy in all three major drivers of mortality in cancer: primary tumors, metastases and stem cell-based relapse. Its LIGHT compound is a small-molecule cancer-targeted imaging agent, which is potential for selective detection of tumors and metastases in a broad range of cancers. Its HOT compound is a small-molecule, broad-spectrum, cancer-targeted molecular radio therapeutic that delivers radiation directly and selectively to cancer cells and cancer stem cells. Its GLOW2 compound is a small-molecule, broad-spectrum, cancer-targeted, non-radioactive optical imaging agent which is potential for intraoperative tumor margin illumination and non-invasive tumor imaging. The company was founded on June 21, 1996 and is headquartered in Madison, WI. | 1 jaar |
Yogo Pratomo | M | 68 |
University of Wisconsin
| 5 jaar |
Boon San Gan | M | 62 |
University of Wisconsin
| 5 jaar |
Steve Shlensky | M | - |
University of Wisconsin
| 7 jaar |
Mike M. Gerdes | M | - |
University of Wisconsin
| 6 jaar |
Terry Sivesind | M | - |
Cellectar, Inc.
Cellectar, Inc. Miscellaneous Commercial ServicesCommercial Services Cellectar, Inc. is a clinical stage radiopharmaceutical company that designs and develops products to detect, treat and monitor a wide variety of human cancers. Cellectar began independent lab activities in February 2003 after forming a company and raising initial funds in the 2000-2002 timeframe. Its product candidates combine phospholipids ethers analogs (PLEs), which are lipid-like molecules, with radioisotopes that destroy or image malignant cancer cells. Because only malignant tumor cells and tissues retain large amounts of these compounds, malignant cancer-selective retention of therapeutic or diagnostic doses of radioactivity can be achieved. Cellectar has demonstrated specific uptake and retention of its product candidates in more than 45 tumor types tested in proof-of-principle preclinical animal studies. In addition, ten preclinical experiments have shown anti-tumor activity in each tumor type studied including breast, prostate, lung, glioma, pancreatic, melanoma, ovarian, uterine, renal and colorectal cancers. The compound, originally known as NM404, is being taken through the regulatory process as CLR1404. Capitalizing on the unique characteristics of malignant cancer cells, Cellectar's molecules will be designed to find, treat and follow malignancies through the delivery of radiopharmaceuticals in a novel, highly selective way. | - |
Brenda Furlow | F | 66 |
TomoTherapy, Inc.
TomoTherapy, Inc. Medical SpecialtiesHealth Technology TomoTherapy, Inc. manufactures and provides radiation treatment systems for advanced radiation therapy. It provides radiation treatment services for cancer patients with its TomoTherapy Hi·Art System, which changes the intensity of the radiation beam so that it adapts to the shape of the tumor. The firm's system focuses on killing cancer cells while sparing healthy tissue. The company was founded by Thomas Rockwell Mackie and Paul J. Reckwerdt in 1997 and is headquartered in Madison, WI. | 4 jaar |
Jay Edwin van Cleave | M | 64 |
University of Wisconsin
| 5 jaar |
Stephen C. Hathaway | M | 68 |
TomoTherapy, Inc.
TomoTherapy, Inc. Medical SpecialtiesHealth Technology TomoTherapy, Inc. manufactures and provides radiation treatment systems for advanced radiation therapy. It provides radiation treatment services for cancer patients with its TomoTherapy Hi·Art System, which changes the intensity of the radiation beam so that it adapts to the shape of the tumor. The firm's system focuses on killing cancer cells while sparing healthy tissue. The company was founded by Thomas Rockwell Mackie and Paul J. Reckwerdt in 1997 and is headquartered in Madison, WI. | 6 jaar |
Charles D. Ebert | M | 70 |
University of Utah
| 8 jaar |
Mike Reckmeyer | M | - |
University of Wisconsin
| 7 jaar |
Paul Leff | M | - |
University of Wisconsin
| 5 jaar |
Jim Stephenson | M | - |
University of Wisconsin
| 6 jaar |
Tom Cole | M | - |
University of Wisconsin
| - |
Robert Piepenburg | M | - |
University of Wisconsin
| 6 jaar |
Kevin O'Malley | M | - |
TomoTherapy, Inc.
TomoTherapy, Inc. Medical SpecialtiesHealth Technology TomoTherapy, Inc. manufactures and provides radiation treatment systems for advanced radiation therapy. It provides radiation treatment services for cancer patients with its TomoTherapy Hi·Art System, which changes the intensity of the radiation beam so that it adapts to the shape of the tumor. The firm's system focuses on killing cancer cells while sparing healthy tissue. The company was founded by Thomas Rockwell Mackie and Paul J. Reckwerdt in 1997 and is headquartered in Madison, WI. | 12 jaar |
Steven Frankel | M | - |
University of Wisconsin
| 5 jaar |
Mark Richard Mirsberger | M | - |
University of Wisconsin
| 6 jaar |
Tom Ray | M | 58 |
University of Wisconsin
| 5 jaar |
Ronald G. Moffitt | M | - |
University of Utah
| 8 jaar |
Christopher J. Pazoles | M | 73 |
Novelos Therapeutics, Inc.
Novelos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Novelos Therapeutics, Inc. is a pharmaceutical company, which is engaged in the development of novel drugs for the treatment and diagnosis of cancer. It comprises of three cancer-targeted compounds: GLOW2, HOT and LIGHT, which are used for the treatment of cancer. Its therapeutic compounds directly kill cancer cells while minimizing harm to normal cells. This offers the potential for a paradigm shift in cancer therapy by providing efficacy in all three major drivers of mortality in cancer: primary tumors, metastases and stem cell-based relapse. Its LIGHT compound is a small-molecule cancer-targeted imaging agent, which is potential for selective detection of tumors and metastases in a broad range of cancers. Its HOT compound is a small-molecule, broad-spectrum, cancer-targeted molecular radio therapeutic that delivers radiation directly and selectively to cancer cells and cancer stem cells. Its GLOW2 compound is a small-molecule, broad-spectrum, cancer-targeted, non-radioactive optical imaging agent which is potential for intraoperative tumor margin illumination and non-invasive tumor imaging. The company was founded on June 21, 1996 and is headquartered in Madison, WI. | 9 jaar |
Greg J. Schroeder | M | - |
University of Wisconsin
| 8 jaar |
Edwin M. Jaehne | M | 71 |
University of Utah
| 5 jaar |
Richard Sneider | M | - |
University of Wisconsin
| 7 jaar |
Statistieken
Land | Connecties | % van het totaal |
---|---|---|
Verenigde Staten | 100 | 100.00% |
Ouderdom van de connecties
Actief
Verleden
Man
Vrouw
Besturend
Uitvoerend
Oorsprong van de connecties